Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic Lateral Sclerosis Treatment Market (Type: Sporadic ALS and Familial ALS; Treatment: Medication, Stem Cell Therapy, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Amyotrophic Lateral Sclerosis Treatment Market Outlook 2031

  • The global industry was valued at US$ 594.1 Mn in 2022
  • It is projected to grow at a CAGR of 5.5% from 2023 to 2031 and reach more than US$ 958.2 Mn by the end of 2031

Analysts’ Viewpoint

Rise in prevalence of amyotrophic lateral sclerosis is driving the global amyotrophic lateral sclerosis (ALS) treatment market. Sporadic ALS is the most common type of ALS, which affects around 90% to 95% of total ALS patients. Increase in awareness among patients and healthcare professionals about new treatment options is expected to propel global amyotrophic lateral sclerosis (ALS) treatment market growth. Emergence of stem cell therapy as a new treatment option for ALS is likely to bolster market expansion.

The COVID-19 pandemic had a negative effect on the overall amyotrophic lateral sclerosis (ALS) treatment market share. Moreover, high cost associated with amyotrophic lateral sclerosis (ALS) treatment is projected to hamper market growth in the near future.

Amyotrophic Lateral Sclerosis Treatment Market

Global Amyotrophic Lateral Sclerosis Treatment Market Introduction

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive and debilitating neurodegenerative disorder that affects the nerve cells responsible for controlling voluntary muscle movement. It was first described by French neurologist Jean-Martin Charcot in the late 19th century.

ALS primarily affects the motor neurons, which are the nerve cells responsible for transmitting signals from the brain and spinal cord to the muscles throughout the body. As the disease progresses, these motor neurons gradually degenerate and die, leading to a loss of muscle control and function.

Amyotrophic lateral sclerosis symptoms typically manifest as muscle weakness, muscle wasting, and a progressive decline in voluntary muscle control. Initial signs could include difficulty with tasks that require fine motor skills, such as buttoning a shirt or writing. As the disease progresses, individuals could experience difficulty walking, speaking, swallowing, and eventually breathing. However, cognitive function is typically preserved in most cases of ALS.

The course of ALS can vary from person to person, but it generally follows a relentless and progressive course, leading to severe disability and ultimately respiratory failure, which is the most common cause of death in ALS patients.

The average amyotrophic lateral sclerosis life expectancy after diagnosis is around two to five years, although some individuals may live longer with appropriate medical care and support. Amyotrophic lateral sclerosis supportive therapy includes physiotherapy, which works to maintain physical function. Occupational therapy helps find strategies for navigating daily life with a chronic condition. Speech therapy helps with speech problems as well as difficulty swallowing.

Rise in Prevalence of Amyotrophic Lateral Sclerosis (ALS)

Increase in prevalence of amyotrophic lateral sclerosis is a major factor projected to drive the global amyotrophic lateral sclerosis treatment market size during the forecast period. Prevalence of ALS has been steadily increasing; an estimated two to five per 100,000 people are affected by ALS worldwide. Here are some factors that contribute to the growing prevalence of ALS:

  • Aging Population: ALS primarily affects individuals between the ages of 40 and 70, and the prevalence of the disease increases with age. As the global population continues to age, there is a higher likelihood of more individuals being diagnosed with ALS.
  • Improved Diagnosis and Awareness: In the past few years, there has been greater awareness about ALS, resulting in improved diagnostic techniques and increased detection rates. Medical professionals are now better equipped to identify the early symptoms of ALS and differentiate it from other conditions with similar presentations.
  • Genetic Factors: 5% to 10% of ALS cases are inherited, meaning they are caused by specific genetic mutations. Advances in genetic testing have allowed for better identification of individuals who carry these mutations, leading to increased diagnosis rates.

Strong Product Pipeline

A robust product pipeline means there are multiple potential treatments in various stages of development, including preclinical studies, clinical trials, and regulatory review. This diversification of treatment options provides hope for patients and physicians, as it increases the likelihood of finding effective therapies to manage ALS.

NurOwn, developed by BrainStorm Cell Therapeutics, is an investigational therapy that utilizes mesenchymal stem cells (MSCs) derived from the patient's bone marrow. These MSCs are modified to secrete factors that support the survival and function of motor neurons. NurOwn has completed phase 3 clinical trials, and results have shown promising outcomes in terms of slowing ALS progression and improving patient function.

AMX0035 is a lead pipeline product by Amylyx Pharmaceuticals. It is a combination therapy consisting of sodium phenylbutyrate and taurursodiol. It aims to protect against neurodegeneration and preserve the health of motor neurons. Phase 2 clinical trials demonstrated a significant slowing of ALS progression and improvement in survival rates.

Thus, strong product pipeline is likely to bolster the global amyotrophic lateral sclerosis treatment market development in the next few years.

High Incidence of Sporadic ALS

In terms of type, the sporadic amyotrophic lateral sclerosis (ALS) segment accounted for the largest global amyotrophic lateral sclerosis (ALS) treatment market share in 2022. Sporadic amyotrophic lateral sclerosis (ALS), often referred to as sporadic ALS or simply ALS, is the most common form of the neurodegenerative disease. ALS is a progressive disorder that affects the nerve cells responsible for controlling voluntary muscle movement in the brain and spinal cord.

Sporadic ALS is the most common form of the disease and accounts for approximately 90% to 95% of all ALS cases. Sporadic ALS is the occurrence of ALS without any apparent family history or genetic predisposition.

It can affect individuals of any age, but it most commonly manifests in people between the ages of 40 and 60. The exact cause of sporadic ALS remains largely unknown, although researchers believe it may result from a complex interaction of genetic, environmental, and lifestyle factors.

Rise in Prevalence of Amyotrophic Lateral Sclerosis Fueling Medication Segment

Based on treatment, the medication segment dominated the global amyotrophic lateral sclerosis (ALS) treatment market demand in 2022. Amyotrophic lateral sclerosis medication includes Rilutek (riluzole) and Radicava (edaravone).

Riluzole is a medication that has shown effectiveness in slowing down the progression of sporadic ALS. It works by reducing the release of glutamate, a neurotransmitter that can contribute to motor neuron damage. Riluzole has demonstrated to modestly extend survival and delay the need for tracheostomy in some patients.

Edaravone is another ALS medication approved for sporadic ALS treatment. It is an antioxidant that aims to reduce oxidative stress, which is believed to contribute to motor neuron degeneration. Edaravone has been shown to slow functional decline in some patients and is typically administered intravenously.

Rise in prevalence of amyotrophic lateral sclerosis and high demand for amyotrophic lateral sclerosis medications are likely to drive the segment during forecast period.

Favorable Reimbursement Policies Propelling Hospital Pharmacies Segment

Based on distribution channel, the hospital pharmacies segment is likely to account for major share of the global amyotrophic lateral sclerosis treatment market during the forecast period. Amyotrophic lateral sclerosis patients need regular hospital visits. The number of patients being treated at hospitals is increasing due to favorable reimbursement policies.

The segment is anticipated to grow at a rapid pace during the forecast period. This is ascribed to rise in awareness about amyotrophic lateral sclerosis and the trend of utilization of new & improved drugs by patients and physicians.

Regional Outlook of Global Amyotrophic Lateral Sclerosis Treatment Industry

As per amyotrophic lateral sclerosis treatment market trends, North America is a major market for amyotrophic lateral sclerosis treatment, with the U.S. being one of the largest markets for these medications. High prevalence of amyotrophic lateral sclerosis, aging population, and increase in demand for innovative treatment options for the disease are driving the market in North America.

Presence of large number of pharmaceutical companies and high awareness about amyotrophic lateral sclerosis treatment are expected to propel the market in North America in the next few years.

Asia Pacific is a rapidly growing market for amyotrophic lateral sclerosis treatment, with countries such as China and India being major markets for amyotrophic lateral sclerosis (ALS) drugs. Additionally, the rapidly growing healthcare sector in the region is expected to augment the market in the coming years.

Analysis of Key Players in Global Amyotrophic Lateral Sclerosis Treatment Market

Expansion of product portfolio and mergers & acquisitions are key strategies adopted by prominent manufacturers in the market. Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, and Sun Pharmaceutical are the prominent players in the market.

Key Developments in Global Amyotrophic Lateral Sclerosis Treatment Market

  • In April 2023, Biogen, Inc. received the USFDA approval of QALSODY for treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene
  • In May 2022, Mitsubishi Tanabe Pharma America, Inc. received the U.S. FDA approval for RADICAVA ORS (edaravone), the oral form of edaravone, for the treatment of amyotrophic lateral sclerosis (ALS)

The amyotrophic lateral sclerosis treatment market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Amyotrophic Lateral Sclerosis Treatment Market Snapshot

Attribute Detail

Size in 2022

US$ 594.1 Mn

Forecast (Value) in 2031

More than US$ 958.2 Mn

Growth Rate (CAGR)

5.5%

Forecast Period

2023-2031

Historical Data Available for

2017-2021

Quantitative Units

US$ Mn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, Porter’s Five Forces analysis, key trends, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Sporadic ALS
    • Familial ALS
  • Treatment
    • Medication
    • Stem Cell Therapy
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC Countries

Companies Profiled

  • Mitsubishi Tanabe Pharma Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • BrainStorm Therapeutics
  • Biogen, Inc.
  • Corestem
  • AB Science
  • F. Hoffmann-La Roche AG
  • Biohaven Pharmaceutical
  • Sun Pharmaceutical

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global amyotrophic lateral sclerosis treatment market in 2022?

It was valued at US$ 594.1 Mn in 2022

How big will the amyotrophic lateral sclerosis treatment industry be in 2031?

It is projected to reach more than US$ 958.2 Mn by 2031

What will be the CAGR of the amyotrophic lateral sclerosis treatment business during the forecast period?

It is anticipated to grow at a CAGR of 5.5% from 2023 to 2031

Which are the key factors driving demand for amyotrophic lateral sclerosis treatment?

Rise in prevalence amyotrophic lateral sclerosis (ALS) and strong product pipeline are propelling the demand for these medications.

Which is the most lucrative region for amyotrophic lateral sclerosis treatment companies?

North America is projected to be the most lucrative region during the forecast period

Who are the prominent players in the global amyotrophic lateral sclerosis treatment sector?

Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen, Inc., Corestem, AB Science, F. Hoffmann-La Roche AG, Biohaven Pharmaceutical, and Sun Pharmaceutical

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Amyotrophic Lateral Sclerosis Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2017-2031

        4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

    5.1. Regulatory Scenario by Region/globally

    5.2. Pipeline Analysis

    5.3. Pricing Analysis

    5.4. COVID-19 Pandemic Impact on Industry

6. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Type, 2017-2031

        6.3.1. Sporadic ALS

        6.3.2. Familial ALS

    6.4. Market Attractiveness Analysis, by Type

7. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Treatment

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Treatment, 2017-2031

        7.3.1. Medication

        7.3.2. Stem Cell Therapy

        7.3.3. Others

    7.4. Market Attractiveness Analysis, by Treatment

8. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017-2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Type, 2017-2031

        10.2.1. Sporadic ALS

        10.2.2. Familial ALS

    10.3. Market Value Forecast, by Treatment, 2017-2031

        10.3.1. Medication

        10.3.2. Stem Cell Therapy

        10.3.3. Others

    10.4. Market Value Forecast, by Distribution Channel, 2017-2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017-2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Treatment

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Type, 2017-2031

        11.2.1. Sporadic ALS

        11.2.2. Familial ALS

    11.3. Market Value Forecast, by Treatment, 2017-2031

        11.3.1. Medication

        11.3.2. Stem Cell Therapy

        11.3.3. Others

    11.4. Market Value Forecast, by Distribution Channel, 2017-2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Treatment

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Type, 2017-2031

        12.2.1. Sporadic ALS

        12.2.2. Familial ALS

    12.3. Market Value Forecast, by Treatment, 2017-2031

        12.3.1. Medication

        12.3.2. Stem Cell Therapy

        12.3.3. Others

    12.4. Market Value Forecast, by Distribution Channel, 2017-2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Type

        12.6.2. By Treatment

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Type, 2017-2031

        13.2.1. Sporadic ALS

        13.2.2. Familial ALS

    13.3. Market Value Forecast, by Treatment, 2017-2031

        13.3.1. Medication

        13.3.2. Stem Cell Therapy

        13.3.3. Others

    13.4. Market Value Forecast, by Distribution Channel, 2017-2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Type

        13.6.2. By Treatment

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Type, 2017-2031

        14.2.1. Sporadic ALS

        14.2.2. Familial ALS

    14.3. Market Value Forecast, by Treatment, 2017-2031

        14.3.1. Medication

        14.3.2. Stem Cell Therapy

        14.3.3. Others

    14.4. Market Value Forecast, by Distribution Channel, 2017-2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017-2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Type

        14.6.2. By Treatment

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2022

    15.3. Company Profiles

        15.3.1. Mitsubishi Tanabe Pharma Corporation

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Product Portfolio

            15.3.1.3. Financial Overview

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. Otsuka Pharmaceutical Co., Ltd.

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Product Portfolio

            15.3.2.3. Financial Overview

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. BrainStorm Therapeutics

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Product Portfolio

            15.3.3.3. Financial Overview

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. Biogen, Inc.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Product Portfolio

            15.3.4.3. Financial Overview

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Corestem

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Product Portfolio

            15.3.5.3. Financial Overview

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. AB Science

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Product Portfolio

            15.3.6.3. Financial Overview

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. F. Hoffmann-La Roche AG

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Product Portfolio

            15.3.7.3. Financial Overview

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Biohaven Pharmaceutical

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Product Portfolio

            15.3.8.3. Financial Overview

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview

        15.3.9. Sun Pharmaceutical

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Product Portfolio

            15.3.9.3. Financial Overview

            15.3.9.4. SWOT Analysis

            15.3.9.5. Strategic Overview

        15.3.10. Other Prominent Players

List of Tables

Table 01: Global Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 02: Global Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031

Table 03: Global Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 04: Global Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 05: North America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 06: North America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031

Table 07: North America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 08: North America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 09: Europe Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 10: Europe Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031

Table 11: Europe Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 12: Europe Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 13: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 14: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031

Table 15: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 16: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 17: Latin America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 18: Latin America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031

Table 19: Latin America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 20: Latin America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 21: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031

Table 22: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017-2031

Table 23: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

Table 24: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

Figure 01: Global Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031

Figure 02: Global Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Type, 2022 and 2031

Figure 03: Global Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Type, 2023-2031

Figure 04: Global Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 05: Global Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Treatment, 2023-2031

Figure 06: Global Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 07: Global Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 08: Global Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Region, 2022 and 2031

Figure 09: Global Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Region, 2023-2031

Figure 10: North America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031

Figure 11: North America Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Type, 2022 and 2031

Figure 12: North America Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Type, 2023-2031

Figure 13: North America Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 14: North America Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Treatment, 2023-2031

Figure 15: North America Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 16: North America Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 17: North America Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Country, 2022 and 2031

Figure 18: North America Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Country, 2023-2031

Figure 19: Europe Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031

Figure 20: Europe Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Type, 2022 and 2031

Figure 21: Europe Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Type, 2023-2031

Figure 22: Europe Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 23: Europe Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Treatment, 2023-2031

Figure 24: Europe Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 25: Europe Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 26: Europe Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 27: Europe Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 28: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031

Figure 29: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Type, 2022 and 2031

Figure 30: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Type, 2023-2031

Figure 31: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 32: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Treatment, 2023-2031

Figure 33: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 34: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 35: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 36: Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 37: Latin America Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031

Figure 38: Latin America Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Type, 2022 and 2031

Figure 39: Latin America Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Type, 2023-2031

Figure 40: Latin America Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 41: Latin America Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Treatment, 2023-2031

Figure 42: Latin America Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 43: Latin America Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 44: Latin America Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 45: Latin America Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 46: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031

Figure 47: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Type, 2022 and 2031

Figure 48: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Type, 2023-2031

Figure 49: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Treatment, 2022 and 2031

Figure 50: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Treatment, 2023-2031

Figure 51: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 52: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Figure 53: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 54: Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

Figure 55: Global Amyotrophic Lateral Sclerosis Treatment Market Share Analysis, by Company, 2022

Copyright © Transparency Market Research, Inc. All Rights reserved